SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Nutrien Ltd. (NTR.TO) trades at a trailing P/E of 21.4, forward P/E of 19.5. Trailing earnings yield is 4.67%, forward earnings yield 5.14%. PEG 0.09 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (75/100, Pass) — P/E is below market average (21.4); PEG ≤ 1.0 — Peter Lynch undervalued (0.09); earnings yield beats bond yields (4.67%).
- Forward P/E 19.5 (down from trailing 21.4) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.09 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 4.67% — roughly competitive with bond yields (~4.3%), moderate risk-reward. Forward yield improves to 5.14% as earnings recover.
Overall SharesGrow Score: 60/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NTR.TO
Valuation Multiples
P/E (TTM)21.4
Forward P/E19.5
PEG Ratio0.09
Forward PEG1.93
P/B Ratio0.00
P/S Ratio1.80
EV/EBITDA0.0
Per Share Data
EPS (TTM)$4.74
Forward EPS (Est.)$5.22
Book Value / Share$0.00
Revenue / Share$56.23
FCF / Share$0.00
Yields & Fair Value
Earnings Yield4.67%
Forward Earnings Yield5.14%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.00 |
$4.46B |
$336M |
7.5% |
| 2017 |
$0.98 |
$4.55B |
$327M |
7.2% |
| 2018 |
$5.72 |
$19.64B |
$3.57B |
18.2% |
| 2019 |
$1.70 |
$20.02B |
$992M |
5% |
| 2020 |
$0.81 |
$20.91B |
$459M |
2.2% |
| 2021 |
$5.52 |
$27.71B |
$3.15B |
11.4% |
| 2022 |
$14.18 |
$37.88B |
$7.66B |
20.2% |
| 2023 |
$2.53 |
$29.06B |
$1.26B |
4.3% |
| 2024 |
$1.36 |
$25.97B |
$674M |
2.6% |
| 2025 |
$4.74 |
$27.36B |
$2.31B |
8.4% |
